Guodong Liu

Dr. Guodong Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2023 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
HZHao Zhang
Hao Zhang
XYXinghai Yue
Xinghai Yue
ZCZhe Chen
Zhe Chen
CLChao Liu
Chao Liu
WWWantao Wu
Wantao Wu
GLGuodong Liu
Guodong Liu
Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal component of the tumor microenvironment. The versatility and sophisticated mechanisms of CAFs in facilitating cancer progression have been elucidated extensively, including promoting cancer angiogenesis and metastasis, inducing drug resistance, reshaping the extracellular matrix, and developing an immunosuppressive microenvironment. Owing to their robust tumor-promoting function, CAFs are considered a promising target for oncotherapy. However, CAFs are a highly heterogeneous group of cells. Some subpopulations exert an inhibitory role in tumor growth, which implies that CAF-targeting approaches must be more precise and individualized. This review comprehensively summarize the origin, phenotypical, and functional heterogeneity of CAFs. More importantly, we underscore advances in strategies and clinical trials to target CAF in various cancers, and we also summarize progressions of CAF in cancer immunotherapy.

28 May 2024 in Medcomm
Verified
Journal Article
Open access
HWHao Wang
Hao Wang
YZYi Zhang
Yi Zhang
HZHao Zhang
Hao Zhang
HCHui Cao
Hui Cao
JMJinning Mao
Jinning Mao
Quan ChengQuan Cheng
Quan Cheng
Currently, tumor treatment modalities such as immunotherapy and targeted therapy have more stringent requirements for obtaining tumor growth information and require more accurate and easy‐to‐operate tumor information detection methods. Compared with traditional tissue biopsy, liquid biopsy is a novel, minimally invasive, real‐time detection tool for detecting information directly or indirectly released by tumors in human body fluids, which is more suitable for the requirements of new tumor treatment modalities. Liquid biopsy has not been widely used in clinical practice, and there are fewer reviews of related clinical applications. This review summarizes the clinical applications of liquid biopsy components (e.g., circulating tumor cells, circulating tumor DNA, extracellular vesicles, etc.) in tumorigenesis and progression. This includes the development process and detection techniques of liquid biopsies, early screening of tumors, tumor growth detection, and guiding therapeutic strategies (liquid biopsy‐based personalized medicine and prediction of treatment response). Finally, the current challenges and future directions for clinical applications of liquid biopsy are proposed. In sum, this review will inspire more researchers to use liquid biopsy technology to promote the realization of individualized therapy, improve the efficacy of tumor therapy, and provide better therapeutic options for tumor patients.

1 August 2024 in Cancer Communications
Verified
Journal Article
Open access
HZHao Zhang
Hao Zhang
LFLi Fu
Li Fu
XLXinwen Leiliang
Xinwen Leiliang
CQChunrun Qu
Chunrun Qu
WWWantao Wu
Wantao Wu
YCYuan Cheng
Yuan Cheng
The intratumoral microbiome (TM) refers to the microorganisms in the tumor tissues, including bacteria, fungi, viruses, and so on, and is distinct from the gut microbiome and circulating microbiota. TM is strongly associated with tumorigenesis, progression, metastasis, and response to therapy. This paper highlights the current status of TM. Tract sources, adjacent normal tissue, circulatory system, and concomitant tumor co‐metastasis are the main origin of TM. The advanced techniques in TM analysis are comprehensively summarized. Besides, TM is involved in tumor progression through several mechanisms, including DNA damage, activation of oncogenic signaling pathways (phosphoinositide 3‐kinase [PI3K], signal transducer and activator of transcription [STAT], WNT/β‐catenin, and extracellular regulated protein kinases [ERK]), influence of cytokines and induce inflammatory responses, and interaction with the tumor microenvironment (anti‐tumor immunity, pro‐tumor immunity, and microbial‐derived metabolites). Moreover, promising directions of TM in tumor therapy include immunotherapy, chemotherapy, radiotherapy, the application of probiotics/prebiotics/synbiotics, fecal microbiome transplantation, engineered microbiota, phage therapy, and oncolytic virus therapy. The inherent challenges of clinical application are also summarized. This review provides a comprehensive landscape for analyzing TM, especially the TM‐related mechanisms and TM‐based treatment in cancer.

3 April 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
HLHong Luo
Hong Luo
HZHao Zhang
Hao Zhang
JMJinning Mao
Jinning Mao
HCHui Cao
Hui Cao
YTYihao Tao
Yihao Tao
GLGuodong Liu
Guodong Liu
Exosomes, the cell-derived small extracellular vehicles, play a vital role in intracellular communication by reciprocally transporting DNA, RNA, bioactive protein, chains of glucose, and metabolites. With great potential to be developed as targeted drug carriers, cancer vaccines and noninvasive biomarkers for diagnosis, treatment response evaluation, prognosis prediction, exosomes show extensive advantages of relatively high drug loading capacity, adjustable therapeutic agents release, enhanced permeation and retention effect, striking biodegradability, excellent biocompatibility, low toxicity, etc. With the rapid progression of basic exosome research, exosome-based therapeutics are gaining increasing attention in recent years. Glioma, the standard primary central nervous system (CNS) tumor, is still up against significant challenges as current traditional therapies of surgery resection combined with radiotherapy and chemotherapy and numerous efforts into new drugs showed little clinical curative effect. The emerging immunotherapy strategy presents convincing results in many tumors and is driving researchers to exert its potential in glioma. As the crucial component of the glioma microenvironment, tumor-associated macrophages (TAMs) significantly contribute to the immunosuppressive microenvironment and strongly influence glioma progressionviavarious signaling molecules, simultaneously providing new insight into therapeutic strategies. Exosomes would substantially assist the TAMs-centered treatment as drug delivery vehicles and liquid biopsy biomarkers. Here we review the current potential exosome-mediated immunotherapeutics targeting TAMs in glioma and conclude the recent investigation on the fundamental mechanisms of diversiform molecular signaling events by TAMs that promote glioma progression.

24 May 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
MSMaoyuan Sun
Maoyuan Sun
YLYan Li
Yan Li
WZWenli Zhang
Wenli Zhang
XGXiang Gu
Xiang Gu
RWRong Wen
Rong Wen
GLGuodong Liu
Guodong Liu

29 January 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
YXYongqi Xiong
Yongqi Xiong
MSMaoyuan Sun
Maoyuan Sun
QYQinhao Yang
Qinhao Yang
WZWenli Zhang
Wenli Zhang
ASAnchao Song
Anchao Song
PXPeng Xue
Peng Xue